ライフサイエンスコーパス: hydroxyacyl-CoA dehydrogenase

1 to aspects of the catalytic mechanism of l-3-hydroxyacyl-CoA dehydrogenase.

2 may have a Glu474Gln mutation in long-chain hydroxyacyl-CoA dehydrogenase.

3 ied as an essential catalytic residue of L-3-hydroxyacyl-CoA dehydrogenase.

4 fer substantially from the classic, type I 3-hydroxyacyl-CoA dehydrogenases.

5 hase, a marker of oxidative metabolism; beta-hydroxyacyl-CoA dehydrogenase, a marker of lipolytic met

6 mumol.min-1.mg protein-1; P < .05) and beta-hydroxyacyl-CoA dehydrogenase activity (normal, 0.27 +/-

7 etabolize fat, as indicated by measures beta-hydroxyacyl-CoA dehydrogenase activity or its ratio to c

8 Consistent with the hypothesis, l-3-hydroxyacyl-CoA dehydrogenase activity was inhibited by

9 protein level, and a tendency for reduced 3-hydroxyacyl-CoA dehydrogenase activity.

10 lactate dehydrogenase, pyruvate kinase and 3-hydroxyacyl-CoA dehydrogenase activity.

11 atty acid transporters CD36 and CPT1 or beta-hydroxyacyl-CoA dehydrogenase activity.

12 Human type II hydroxyacyl-CoA dehydrogenase/amyloid-beta binding alcoh

13 a 6.1-fold decrease in the kcat/k(m) of L-3-hydroxyacyl-CoA dehydrogenase and a 10-fold increase in

14 ildren had a deficiency only of long-chain 3-hydroxyacyl-CoA dehydrogenase and presented with hypoket

15 long-chain enoyl-CoA hydratase, long-chain 3-hydroxyacyl-CoA dehydrogenase, and long-chain 3-ketoacyl

16 he only histidine conserved in all known L-3-hydroxyacyl-CoA dehydrogenases, and since its counterpar

17 f which (2-trans enoyl-CoA hydratase and L-3-hydroxyacyl-CoA dehydrogenase) are core activities requi

18 endent pathway is the higher activity of L-3-hydroxyacyl-CoA dehydrogenase as compared with Delta3,De

19 n from a peroxisomal enoyl-CoA hydratase/l-3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme gene p

20 tic functions of human brain short chain L-3-hydroxyacyl-CoA dehydrogenase could weaken the protectiv

21 hway and D-3-hydroxyacyl-CoA dehydratase/D-3-hydroxyacyl-CoA dehydrogenase (D-PBE) of the noninducibl

22 metabolic disease states correlated with L-3-hydroxyacyl-CoA dehydrogenase deficiencies.

23 In 24 children with 3-hydroxyacyl-CoA dehydrogenase deficiency, we used DNA am

24 Toxoplasma consisting of one N-terminal d-3-hydroxyacyl-CoA dehydrogenase domain fused to two tandem

25 renal function include enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (EHHADH) and apolipoprotei

26 A novel L-3-hydroxyacyl-CoA dehydrogenase from human brain has been

27 The human short chain L-3-hydroxyacyl-CoA dehydrogenase gene is organized into six

28 RAP150, to the mouse enoyl-CoA hydratase/l-3-hydroxyacyl-CoA dehydrogenase gene promoter.

29 tion is encoded by the human short chain L-3-hydroxyacyl-CoA dehydrogenase gene.

30 l-3-Hydroxyacyl-CoA dehydrogenase (HAD), the penultimate enz

31 and glucose; (3) an increase in muscle beta-hydroxyacyl-CoA dehydrogenase (HADH) and adipose lipopro

32 teroid dehydrogenase type 10/short chain L-3-hydroxyacyl-CoA dehydrogenase have been investigated.

33 yl-CoA oxidase (ACOX), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), and thiolase, has be

34 se (THIO), peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), peroxisomal membrane

35 Measurement of the activity of L-3-hydroxyacyl-CoA dehydrogenase in cultured skin fibroblas

36 The activity of beta-hydroxyacyl-CoA dehydrogenase increased with GW610742 (P

37 ain (C18:0) substrates, whereas the MFP2 L-3-hydroxyacyl-CoA dehydrogenase is active on C6:0, C12:0 a

38 f the second enzyme, enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-PBE) of the inducible p

39 udy, the function of enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase (L-PBE), the second enzyme

40 purification of human brain short chain L-3-hydroxyacyl-CoA dehydrogenase made it possible to charac

41 that His450 is the catalytic residue of L-3-hydroxyacyl-CoA dehydrogenase of the E. coli multifuncti

42 roperties of 3-ketoacyl-CoA thiolase and l-3-hydroxyacyl-CoA dehydrogenase of the mutant complexes we

43 2-terminal hydratase and the COOH-terminal 3-hydroxyacyl-CoA dehydrogenase, result in a unique neurom

44 l-3-Hydroxyacyl-CoA dehydrogenase reversibly catalyzes the c

45 Human heart short chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) catalyzes the oxid

46 Sequencing of the short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) genomic DNA from t

47 with inactivating mutations of short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD) was examined in mi

48 Human brain short chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) was found to catal

49 mutations in the gene encoding short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), a ubiquitously ex

50 Exercise training increased mtDNA and beta-hydroxyacyl-CoA dehydrogenase similarly in WT and CD36-K

51 nsferase, carnitine palmitoyltransferase 1A, hydroxyacyl-CoA-dehydrogenase, Sirtuin 6 (SIRT6), and AM

52 a-peptide (Abeta)-binding protein (ERAB)/L-3-hydroxyacyl-CoA dehydrogenase type II (HADH II) is expre

53 Here, we report that L-3-hydroxyacyl-CoA dehydrogenase type II/amyloid binding al

54 -/-) hearts, we measured the activity of l-3-hydroxyacyl-CoA dehydrogenase, which was acetylated in t

55 37 +/- 8% versus O(TR) 97 +/- 33%) and beta-hydroxyacyl-CoA-dehydrogenase (Y(TR) 31 +/- 7%, versus O